Please assess the completion status of the following clinical trial:

Trial Title: Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed metastatic or unresectable melanoma with V600E mutation~* Measurable disease~* May have received prior immunotherapy (excluding interleukin 2)~* Life expectancy greater than 3 months~* Recovered from effects of previous surgery and/or traumatic injury~* Must agree to use effective contraception~Exclusion Criteria:~* Pregnant or breastfeeding~* Psychological, familial or other conditions that could hamper compliance with protocol~* Receiving other study agents~* History of carcinomatous meningitis~* Known active brain metastases~* Have received a BRAF inhibitor~* Uncontrolled intercurrent illness~* HIV positive on antiretroviral therapy~* History of a different malignancy within past 5 years (except cervical cancer in situ or basal/squamous cell carcinoma of the skin)~* Active hepatitis B or C~* Have received allogenic bone marrow transplant or organ transplant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment Arm (Type: EXPERIMENTAL): Oral vemurafenib 960 milligrams twice a day plus intravenous aldesleukin 600,000 IU/kg every eight hours to tolerance (maximum 14 doses) over five days on days 15-19 of cycle 1 and on days 1-5 of cycle 2. (A cycle is 28 days)~The first course of treatment will consist of three 28-day cycles (12 weeks): 2 weeks of lead-in vemurafenib plus 3 weeks on IL-2 plus 7 weeks wait.~A second course may be given at the discretion of the investigator, if there is evidence of tumor stability or regression.

Based on this trial design, predict the completion outcome and termination type (if applicable).